Kymera Therapeutics KYMR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$315M-1.2% | -$311.35M-5.5% | -$295.12M-7.1% | -$275.43M-14.3% | -$240.88M-7.6% | ||
| $8.29M-0.3% | $8.31M+0.5% | $8.27M+2.0% | $8.11M+1.8% | $7.96M+8.0% | ||
| $61.68M+3.0% | $59.9M+1.1% | $59.25M+1.5% | $58.35M+1.9% | $57.28M+4.1% | ||
| —— | $3.86M— | —— | —— | —— | ||
| $2.93M+249% | -$1.97M-99.8% | -$988K-57.1% | -$629K-118% | $3.54M+1,251% | ||
| —— | —— | —— | —— | —— | ||
| $13.77M+85.3% | $7.43M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $17.55M+150% | -$34.92M+15.0% | ||
| -$242.58M-4.2% | -$232.89M-2.2% | -$227.93M+9.2% | -$251.01M-7.2% | -$234.06M-20.3% | ||
| $1.42M-2.3% | $1.45M-36.4% | $2.28M+8.6% | $2.1M-65.6% | $6.09M-53.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$712.52M-36.7% | -$521.06M— | —— | —— | —— | ||
| $19.19M— | $0— | —— | —— | —— | ||
| $1.64M+9.9% | $1.49M+9.0% | $1.37M-13.9% | $1.59M+1.9% | $1.56M-0.8% | ||
| $1.01B+1.9% | $990.71M+244% | $288.26M-42.3% | $499.67M+95.7% | $255.35M-58.1% | ||
| $54.13M-77.1% | $236.76M+10,489% | $2.24M-99.2% | $268.18M+7,629% | -$3.56M-135% | ||
| $300K-3.8% | $312K+4.3% | $299K+10.7% | $270K+15.4% | $234K+13.6% | ||
| —— | $3.86M-6.5% | $4.12M-6.1% | $4.39M-5.7% | $4.66M-5.4% | ||
| —— | —— | —— | -$1.7M-109% | $17.97M+738% | ||
| -$5.25M-4.0% | -$5.04M— | —— | —— | —— | ||
| -$2.61M+2.2% | -$2.67M+2.3% | -$2.73M-2.6% | -$2.66M-2.5% | -$2.6M-2.1% | ||
| —— | $18K+128% | -$64K+56.2% | -$146K+36.0% | -$228K+26.5% | ||
| —— | —— | —— | $9.13M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -$656.23M-33.3% | -$492.17M-50.0% | -$328.12M-100% | -$164.06M— | ||
| $80.28M+30.3% | $61.62M+312% | $14.96M-3.2% | $15.47M+84.3% | $8.39M-28.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $1.03M-29.4% | $1.46M-22.7% | $1.89M-18.5% | $2.31M-15.6% | ||
| -$244M-4.1% | -$234.34M-1.8% | -$230.21M+9.0% | -$252.92M-5.4% | -$239.96M-15.7% | ||
| -$244M-4.1% | -$234.34M-1.8% | -$230.21M+9.0% | -$252.92M-5.4% | -$239.96M-15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
